BCLI Brainstorm Cell Therapeutics In

4.04
-0.03  -1%
Previous Close 4.07
Open 4.03
Price To book 7.68
Market Cap 75.50M
Shares 18,687,000
Volume 29,784
Short Ratio 3.24
Av. Daily Volume 206,829

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17841006
  2. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17722237
  3. 8-K - Current report 17668045
  4. 8-K - Current report 17657080
  5. 8-K - Current report 162057741

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released July 2016. Phase 3 trial to be initiated 2Q 2017.
NurOwn
Amytrophic lateral sclerosis (ALS)

Latest News

  1. BrainStorm to Present at Cell & Gene Exchange Conference in Washington DC
  2. BrainStorm Initiated Technology Transfer to City of Hope for U.S. Production of NurOwn® for Phase 3 ALS Study
  3. BrainStorm Announces First Quarter 2017 Financial Results and Provides Corporate Update
  4. BCLI: Approval of Edaravone Shows FDA’s Eagerness to Approve New Treatments for ALS
  5. BrainStorm to Present at Two Scientific Conferences in May
  6. BrainStorm Announces Publication of NurOwn® Autism Research Study
  7. Today's Research Reports on Biotech Stocks to Watch: Brainstorm Cell Therapeutics and Cyclacel Pharmaceuticals
  8. BrainStorm Announces Financial Results for 2016 and Provides Business Update
  9. BrainStorm CEO to Present at the Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum
  10. Israel's BrainStorm names Biogen senior executive Kern as COO
  11. BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer
  12. BrainStorm Announces MOU with Tel Aviv Sourasky Medical Center to Make NurOwn® Available to Patients as a Hospital Exemption Product
  13. BrainStorm Names Dr. June S. Almenoff and Arturo O. Araya to its Board of Directors as Company Prepares for Clinical and Commercial Success
  14. BCLI: Seeking Early Regulatory Approval in Canada for NurOwn® in ALS
  15. Biotech's Rise Shows No Sign of Slowing Dow in 2017: Today's Reports on Pernix Therapeutics and Brainstorm Cell Therapeutics
  16. BrainStorm Seeks ALS Drug Approval In Canada
  17. BrainStorm Seeking Approval To Distribute NurOwn® in Canada
  18. BrainStorm seeks early approval for stem cell treatment in Canada

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17841006
  2. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17722237
  3. 8-K - Current report 17668045
  4. 8-K - Current report 17657080
  5. 8-K - Current report 162057741
  6. 8-K - Current report 162042869
  7. 8-K - Current report 162032594
  8. EFFECT - Notice of Effectiveness 162011652
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 161996490
  10. POS AM - Post-Effective amendments for registration statement 161996425